Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | GRO-a | 136.0 | 51 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | GRO-a | 7309.0 | 59 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | GRO-a | 297.0 | 61 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | GRO-a | 2334.0 | 42 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | GRO-a | 1933.0 | 30 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | GRO-a | 18203.5 | 44 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | GRO-a | 19757.0 | 35 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 2 | GRO-a | 18706.0 | 41 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | GRO-a | 13239.0 | 49 | |
N2645 | IL-1 alpha | 100 | ng/mL | 2 | GRO-a | 13121.0 | 48 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | GRO-a | 19848.0 | 44 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 2 | GRO-a | 20191.0 | 45 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | GRO-a | 100.0 | 29 | |
RA2159 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | GRO-a | 5018.5 | 42 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | GRO-a | 45.0 | 42 | |
N2645 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | GRO-a | 50.5 | 42 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | GRO-a | 1113.0 | 45 | |
RA2708 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | GRO-a | 10103.0 | 37 | |
RA2159 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 2 | GRO-a | 14829.0 | 41 | |
RA2159 | Poly(I:C) | 2 | ug/mL | 2 | GRO-a | 17861.0 | 35 | ||||
N2645 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 2 | GRO-a | 962.5 | 56 | |
N2645 | Poly(I:C) | 2 | ug/mL | 2 | GRO-a | 3472.0 | 41 | ||||
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 2 | GRO-a | 19117.0 | 37 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 2 | GRO-a | 18272.0 | 35 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | 2 | GRO-a | 88.0 | 41 |